COMMUNIQUÉS West-GlobeNewswire

Context Therapeutics to Present at the Jefferies Global Healthcare Conference
27/05/2026
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
27/05/2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and [...]
Agomab Announces Results of Annual General Meeting
27/05/2026
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM [...]
BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments
27/05/2026
BrewDog Launches Multi-Channel “Underdog” Campaign Across Retail, Bars and Digital Media — Including a Nationwide “Win a Year of Beer” Contest and Destination Match-Day Watch Parties Across the U.K. ELLON, United [...]
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions
27/05/2026
Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of obesity MitoRx Chief Scientific Officer Xavier Jacq to also participate in panel and deliver corporate [...]
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
27/05/2026
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart [...]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
27/05/2026
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented [...]
Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships
27/05/2026
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services French Ministry approval recognizes Intravacc as a private research [...]
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
27/05/2026
Press release – No. 10 / 2026 Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater [...]
Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
27/05/2026
Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with Dalton Tx ’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS [...]
Intravacc obtient l’agrément CIR en France pour accompagner ses partenariats en R&D vaccinale
27/05/2026
Valable pour la période 2025–2027, cet agrément permet aux entreprises innovantes françaises de faire appel à l’expertise d’Intravacc dans le développement de vaccins, le développement analytique et la fabrication [...]
New study reveals promising new way to find serious liver disease earlier
27/05/2026
SOMERSET, United Kingdom and BARCELONA, Spain, May 27, 2026 (GLOBE NEWSWIRE) -- Predictive Health Intelligence today announced a promising new way to identify people with serious liver disease earlier, using existing [...]
Remarcate Limited Liability Company Expands Into U.S. Market to Support Hispanic Healthcare Providers With AI-Driven Patient Acquisition Systems
27/05/2026
WESLEY CHAPEL, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Remarcate Limited Liability Company, a Florida-based healthcare marketing and patient acquisition company, announced the expansion of its operations into the United [...]
argenx to Present at Upcoming Investor Conferences
27/05/2026
May 27, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
27/05/2026
Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO—a certified algorithm developed by the [...]
Vireo Growth Inc. Exercises Option to Purchase New York Facility from Innovative Industrial Properties
27/05/2026
MINNEAPOLIS, May 26, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that its subsidiary, 256 County Route 117 Perth LLC (the “Buyer”), completed the [...]
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
27/05/2026
SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
26/05/2026
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
26/05/2026
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data [...]

Pages